$190 Million is the total value of Foresite Capital Management I, LLC's 4 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TXG | Sell | 10X Genomics, Inc. | $177,000,000 | -48.4% | 1,250,000 | -54.5% | 93.12% | -3.5% |
| NVAX | Novavax, Inc. | $7,450,000 | +2.9% | 66,810 | 0.0% | 3.92% | +92.3% | |
| EPZM | Buy | Epizyme, Inc. | $3,190,000 | +9.7% | 293,759 | +20.5% | 1.68% | +104.9% |
| XLRN | Acceleron Pharma Inc. | $2,444,000 | +13.7% | 19,100 | 0.0% | 1.29% | +112.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Acceleron Pharma Inc. | 16 | Q3 2021 | 43.0% |
| 10X Genomics, Inc. | 12 | Q3 2022 | 100.0% |
| Epizyme, Inc. | 8 | Q1 2022 | 1.7% |
| Orexigen Therapeutics, Inc. | 7 | Q3 2015 | 44.3% |
| BioDelivery Sciences International, Inc. | 7 | Q3 2015 | 29.3% |
| Karyopharm Therapeutics Inc. | 5 | Q4 2014 | 55.1% |
| Xencor, Inc. | 5 | Q4 2014 | 13.8% |
| Novavax, Inc. | 5 | Q3 2021 | 10.8% |
| Ignyta, Inc. | 5 | Q1 2015 | 15.4% |
| Ambit Biosciences Corporation | 4 | Q3 2014 | 30.7% |
View Foresite Capital Management I, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-13 |
View Foresite Capital Management I, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.